An international study to increase concordance in Ki67 scoring

Modern Pathology

Volumn 28, Issue 6, 2015, Pages 778-786

  Polley, Mei Yin C ^a   Leung, Samuel C Y ^b   Gao, Dongxia ^b   Mastropasqua, Mauro G ^c   Zabaglo, Lila A ^d   Bartlett, John M S ^e   Mcshane, Lisa M ^a   Enos, Rebecca A ^f   Badve, Sunil S ^g   Bane, Anita L ^h   Borgquist, Signe ⁱ   Fineberg, Susan ^j   Lin, Ming Gang ^k   Gown, Allen M ^l   Grabau, Dorthe ⁱ   Gutierrez, Carolina ^m   Hugh, Judith C ⁿ   Moriya, Takuya ^o   Ohi, Yasuyo ^p   Osborne, C Kent ^m   Penault Llorca, Frédérique M ^q   Piper, Tammy ^r   Porter, Peggy L ^k   Sakatani, Takashi ^s   Salgado, Roberto ^t   Starczynski, Jane ^u   Lænkholm, Anne Vibeke ^v   Viale, Giuseppe ^w   Dowsett, Mitch ^x   Hayes, Daniel F ^y   Nielsen, Torsten O ^b   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^f EMMES CORPORATION   (United States)

^g INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h MCMASTER UNIVERSITY   (Canada)

ⁱ LUND UNIVERSITY   (Sweden)

^j MONTEFIORE MEDICAL CENTER   (United States)

^k Fred Hutchinson Cancer Research Center   (United States)

^l PHENOPATH LABORATORIES   (United States)

^m BAYLOR COLLEGE OF MEDICINE   (United States)

ⁿ UNIVERSITY OF ALBERTA   (Canada)

^o KAWASAKI MEDICAL SCHOOL   (Japan)

^p SAGARA HOSPITAL   (Japan)

^q CENTRE JEAN PERRIN   (France)

^r WESTERN GENERAL HOSPITAL   (United Kingdom)

^s JICHI MEDICAL UNIVERSITY   (Japan)

^t JULES BORDET INSTITUTE   (Belgium)

^u UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^v SLAGELSE HOSPITAL   (Denmark)

^w UNIVERSITY OF MILAN   (Italy)

^x ROYAL MARSDEN HOSPITAL   (United Kingdom)

^y UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

ARTICLE; ASSESSMENT OF HUMANS; BREAST CANCER; CALIBRATION; CANCER CELL; CANCER DIAGNOSIS; COMPUTER PROGRAM; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; KI67 SCORING; LABORATORY; PRIORITY JOURNAL; SECONDARY ANALYSIS; TISSUE MICROARRAY; TUMOR INVASION; BREAST TUMOR; CLINICAL TRIAL; FEMALE; IMMUNOHISTOCHEMISTRY; MULTICENTER STUDY; PATHOLOGY; STANDARDS;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; TISSUE ARRAY ANALYSIS;

EID: 84930177652     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2015.38     Document Type: Article

References (22)

1. Dowsett M, Nielsen TO, A'Hern R et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656-1664
2. Goldhirsch A, Wood WC, Coates AS et al. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011;22:1736-1747
3. Inwald EC, Klinkhammer-Schalke M, Hofstadter F et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 2013;139: 539-552
4. Viale G, Giobbie-Hurder A, Regan MM et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1-98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol 2008;26: 5569-5575
5. Yerushalmi R, Woods R, Ravdin PM et al. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010;11:174-183
6. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007;25:5287-5312
7. Luporsi E, Andre F, Spyratos F et al. Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat 2012;132: 895-915
8. Goldhirsch A, Winer EP, Coates AS et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol 2013;24:2206-2223
9. Polley MY, Leung SC, McShane LM et al. An international Ki67 reproducibility study. J Natl Cancer Inst 2013;105:1897-1906
10. Genetic Pathology Evaluation Centre Ki67-QC calibrator [http://www.gpec.ubc.ca/calibrator]
11. Mikami Y, Ueno T, Yoshimura K et al. Interobserver concordance of Ki67 labeling index in breast cancer: Japan Breast Cancer Research Group Ki67 Ring Study. Cancer Sci 2013;104:1539-1543
12. Tang LH, Gonen M, Hedvat C et al. Objective quantification of the ki67 proliferative index in neuroendocrine tumors of the gastroenteropancreatic system: a comparison of digital image analysis with manual methods. Am J Surg Pathol 2012;36:1761-1770
13. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull 1971;76:378-382
14. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-1452
15. Hayes DF. From genome to bedside: are we lost in translation? Breast 2013;22 Suppl 2:S22-S26
16. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013;31: 3997-4013
17. Wolff AC, Hammond ME, Hicks DG et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med 2014;138:241-256
18. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med 2010;134:907-922
19. Hammond ME, Hayes DF, Dowsett M et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010;28: 2784-2795
20. Varga Z, Diebold J, Dommann-Scherrer C et al. How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One 2012;7:e37379
21. Ellis MJ, Tao Y, Luo J et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100:1380-1388
22. Cheang MC, Chia SK, Voduc D et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-750